Q-omics provides the consensus-scored LIN7B profile across patient tissues and cancer cell-line models. LIN7B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LIN7B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, LIN7B protein abundance shows 17,818 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where LIN7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN7B survival associations across molecular data types. LIN7B RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN7B RNA expression–survival associations across cancer types. High LIN7B expression shows unfavorable associations in ACC, KIRC, BRCA and UCS, but favorable associations in PAAD and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for LIN7B RNA expression.
This table summarizes LIN7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for LIN7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN7B shows lower tumor expression in KICH and PRAD and higher tumor expression in LIHC, LUSC, CHOL and BLCA. The LIHC box plot shows higher LIN7B RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with LIN7B in patient tissues and cancer cell lines. In patient samples, LIN7B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
